SCHEMBL5873946

SCHEMBL5873946

O=C1Nc2ncc(-c3ccsc3)cc2C1=CNc1ccccc1CCO

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 1/20 0.37
HIF1A Q16665 1/20 0.36
CHEK2 O96017 6/20 0.35
CHEK1 O14757 2/20 0.35
MAP3K11 Q16584 2/20 0.35
PDGFRB P09619 2/20 0.33
PDGFRA P16234 2/20 0.33
GAK O14976 1/20 0.33
CDK8 P49336 1/20 0.33
EEF2K O00418 1/20 0.32
DYRK3 O43781 1/20 0.32
JAK2 O60674 1/20 0.32
RPS6KA5 O75582 1/20 0.32
PRKD3 O94806 1/20 0.32
MAP4K4 O95819 1/20 0.32
CDK1 P06493 1/20 0.32
PIM1 P11309 1/20 0.32
CLK2 P49760 1/20 0.32
CDK5 Q00535 1/20 0.32
CAMK2B Q13554 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5873944 1.00 JAK3 (0.37) JAK3HIF1ACHEK2CHEK1MAP3K11
SCHEMBL6873793 0.89 JAK3 (0.42) JAK3HIF1ACHEK2CHEK1MAP3K11
SCHEMBL6873796 0.89 JAK3 (0.42) JAK3HIF1ACHEK2CHEK1MAP3K11
SCHEMBL6884674 0.82 RET (0.36) JAK3CHEK2CHEK1MAP3K11EEF2K
SCHEMBL6884680 0.82 RET (0.36) JAK3CHEK2CHEK1MAP3K11EEF2K
SCHEMBL5873722 0.82 NTRK1 (0.45) JAK3CDK1
SCHEMBL6884688 0.82 NTRK1 (0.45) JAK3CDK1
SCHEMBL6880641 0.81 MAP3K11 (0.47) JAK3MAP3K11PDGFRBPDGFRAAXL
SCHEMBL6880635 0.81 MAP3K11 (0.47) JAK3MAP3K11PDGFRBPDGFRAAXL
SCHEMBL6884634 0.81 KDR (0.36) JAK3CHEK2CHEK1MAP3K11PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818632-B2 3-(anilinomethylene)oxindoles SMITHKLINE BEECHAM CORPORATION 2004-11-16 US claimed
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia GLENNON KIMBERLEY CAROLINE (US) 2002-07-25 US claimed
EP-1165514-A1 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2002-01-02 EP claimed
WO-2000056710-A1 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2000-09-28 WO claimed
US-7129253-B2 Compounds SMITHKLINE BEECHAM CORPORATION (US) 2006-10-31 US disclosed
US-6818632-B2 3-(anilinomethylene)oxindoles SMITHKLINE BEECHAM CORPORATION 2004-11-16 US disclosed
US-20040191210-A1 Compounds GLENNON KIMBERLEY CAROLINE (US) 2004-09-30 US disclosed
US-6498176-B1 INHIBITING TUMOR GROWTH VIA INHIBITION OF TUMOR-RELATED ANGIOGENESIS SMITHKLINEBEECHAM CORPORATION 2002-12-24 US disclosed
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia GLENNON KIMBERLEY CAROLINE (US) 2002-07-25 US disclosed
US-6350747-B1 PROTEIN SERINE/THREONINE KINASE AND PROTEIN TYROSINE KINASE ENZYME INHIBITORS; ANGIOGENESIS INHIBITORS; ANTITUMOR AND ANTIPROLIFERATIVE AGENTS GLAXO WELLCOME INC. 2002-02-26 US disclosed
EP-1165514-A1 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2002-01-02 EP disclosed
WO-2000056710-A1 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2000-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040191210-A1 Compounds CDK1, AKT1, RPS6KA1 JAK3 439/4885HIF1A 3818/4885CHEK2 38/4885
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia PRKDC, PRKX, BMX JAK3 173/4885HIF1A 2862/4885CHEK2 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.